WealthOne’s Jazz Pharmaceuticals JAZZ Stock Holding History

WealthOne’s Portfolio JAZZ Stock Details JAZZ Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q1	–	Sell	-10	Closed	-$1K	–	319
2018 Q4	$1K	Buy	+10	New	+$1.48K	﹤0.01%	578

Other funds holding JAZZ

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

TCIM

TIAA CREF Investment Management New York $141B AUM 14.18% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Boston Partners Boston, Massachusetts $113B AUM 38.87% 1-Year Est. Return

Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return

Putnam Investments Boston, Massachusetts $75.7B AUM 34.45% 1-Year Est. Return

WealthOne's JAZZ Position: Q1 2019 in Review

WealthOne sold out of Jazz Pharmaceuticals (JAZZ) in Q1 2019, closing a stake of 10 shares — an estimated $1K sold.

WealthOne first reported a position in JAZZ in Q4 2018 and held it in 1 quarter. The position peaked at $1K in Q4 2018. 427 funds tracked by Wall St. Rank hold JAZZ as of Q1 2019.

WealthOne reported no remaining Jazz Pharmaceuticals position as of Q1 2019 after selling out during the quarter.
WealthOne sold 10 Jazz Pharmaceuticals shares in Q1 2019, an estimated $1K.
WealthOne first reported a position in Jazz Pharmaceuticals in Q4 2018 and held it in 1 quarter.
WealthOne's Jazz Pharmaceuticals position peaked at $1K in Q4 2018.
427 funds tracked by Wall St. Rank held Jazz Pharmaceuticals as of Q1 2019.

Based on WealthOne's 13F filing for Q1 2019, filed 16 May 2019.